restricting the use of Trovan (trovafloxacin)

July 1999

The FDA is restricting the use of Trovan (trovafloxacin)...too many cases of severe hepatotoxicity.

Since Trovan came out last year, there have been over 100 reports of hepatotoxicity...including 6 deaths.

Now the FDA recommends Trovan ONLY for patients with potentially life-threatening infections...who begin therapy in hospitals or long-term care facilities.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote